TrialThe Journal of clinical endocrinology and metabolism2010

Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.

Renata Belfort et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.